Loading patent…
OwnerSiegfried Hekimi, Abdelmadjid Hihi +3inventors
InventorsSiegfried Hekimi, Abdelmadjid Hihi, Francoise Levavasseur, Eric Shoubridge, Yuan Gao
Estimating the term…
The present invention relates to a method of screening for a compound allowing survival of clk1 homozygous mutant embryos; a method of screening for a compound suitable for rescue of mutant phenotype of mclk1 homozygous cell line; a method of screening for a compound suitable for partial or complete functional replacement of endogenous ubiquinone; a method for screening a compound capable of inhibiting activity of clk-1 and/or other processes required to make ubiquinone from demethoxyubiquinone; a non-ubiquinone-producer mouse; a DNA construct, which comprises an alteration of mclk1; a non-ubiquinone-producer ES cell line; a coq-3 mutant subject non-ubiquinone producer, a method of screening for a compound suitable for complete or partial functional ubiquinone or demethoxyubiquinone replacement; a method for reducing and/or increasing ubiquinone level in a multicellular subject; a method of screening for a genetic suppressor of clk-1; and a method of screening for a genetic suppressor of coq-3.
1-25. (Canceled)
A mouse comprising a knock-out of a murine clk-1 gene, wherein said mouse exhibits an increased life span relative to a wild-type mouse.
27 (Canceled)
A mouse cell comprising a knock-out of a murine clk-1 gene.
29-41. (Canceled)
A mouse embryo comprising a plurality of cells which comprise a knock-out of a murine clk-1 gene.
66- The mouse embryo of claim 62, wherein the knock-out of the murine clk-1 gene is tissue-specific or organ-specific.
Dependencies are inferred from the claim text.